Targeting glycoprotein VI to disrupt platelet-mediated tumor cell extravasation

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Activated platelets shield circulating tumor cells (CTCs) from blood shear stress and immune detection.
• Platelets promote cancer metastasis by releasing TGF-β1, inducing epithelial-mesenchymal transition in tumor cells, facilitating extravasation, and forming metastatic niches.

Purpose of the Study:

• To explore targeting the platelet-tumor cell axis for cancer therapy.
• To identify therapeutic strategies that disrupt platelet-mediated tumor cell protection and dissemination without compromising hemostasis.

Main Methods:

• Review of the literature on platelet-tumor cell interactions.
• Focus on the role of glycoprotein VI (GPVI) and galectin-3 in platelet activation and CTC aggregation.
• Analysis of the GPVI/FcR γ-chain complex as a therapeutic target.

Main Results:

• Tumor cell-expressed galectin-3 binds to platelet GPVI, activating platelets.
• This interaction forms a protective coat around CTCs, promoting their survival and spread.
• Targeting the GPVI/FcR γ-chain complex can inhibit this pro-metastatic platelet activation.

Conclusions:

• The GPVI/FcR γ-chain complex is a promising target to disrupt the platelet-tumor cell amplification loop.
• Inhibiting galectin-3-mediated platelet activation offers a strategy to reduce cancer metastasis.
• This approach has the potential to selectively block pro-metastatic platelet functions while preserving hemostatic roles.